Prognostic Values of Baseline 18F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma
Table 3
Univariate analysis for survivals.
PFS
OS
HR
95% CI
HR
95% CI
Sex (male)
0.766
0.305-1.927
0.571
2.232
0.787-6.333
0.131
2.124
0.861-5.239
0.102
2.894
1.056-7.932
0.039
B symptoms
1.837
0.781-4.321
0.164
1.501
0.586-3.848
0.398
Ann Arbor stage (III/IV)
1.430
0.529-3.866
0.381
1.685
0.574-4.946
0.342
5.536
1.259-24.350
0.024
10.660
2.063-55.020
0.005
BM involvement
0.917
0.274-3.070
0.889
1.337
0.337-5.310
0.680
LDH
1.261
0.535-2.973
0.595
1.757
0.677-4.561
0.247
3.206
1.296-7.929
0.012
4.954
1.801-13.630
0.002
NCCN-IPI 4-8
2.370
0.886-6.339
0.086
4.610
1.507-14.100
0.007
2.032
0.747-5.524
0.165
3.615
1.167-11.200
0.026
No. of extranodal
2.128
0.881-5.140
0.093
1.584
0.604-4.149
0.350
7.004
2.802-17.510
<0.001
6.467
2.387-17.520
<0.001
8.233
3.370-20.110
<0.001
8.365
3.163-22.120
<0.001
3.193
1.220-8.353
0.018
4.278
1.488-12.300
0.007
Note: Statistically significant. Abbreviations: ECOG: Eastern Cooperative Oncology Group; BM: bone marrow; IPI: International Prognostic Index; NCCN-IPI: National Comprehensive Cancer Network International Prognostic Index; PIT: prognostic index for T-cell lymphoma.
